ClinicalTrials.gg

Program

IBI311

A development code. Also written as “IBI311 (20 mg)”, “IBI311 (3-20 mg)” and “IBI311 (10 mg)”.

Its studies are mostly in Graves Ophthalmopathy, led by Innovent Biologics.

Furthest: phase 3, since Mar 6, 20235 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics51 open or runningphase 3since Mar 6, 2023Jul 15, 2022Dec 31, 2026phase 3 · NCT07113262

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2022First study: phase 1 study in HealthyFirst studyNCT05480579 · 28 enrolled · China
  2. Mar 6, 2023Phase 3 study in Graves OphthalmopathyNCT05795621 · 115 enrolled · China
  3. Oct 19, 2023Phase 3 study in Graves OphthalmopathyNCT06126783 · 91 enrolled · China
  4. Jul 24, 2024Phase 2 study in Graves OphthalmopathyNCT06525506 · 38 enrolled · China
  5. Jul 28, 2025Phase 3 study in Graves OphthalmopathyNCT07113262 · 111 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Graves OphthalmopathyNCT07113262

TargetBeta

IGF1R →read by rule
“IBI311 is a fully human anti-IGF-1R mAb.”study text, by rule · the study

Other programs on IGF1R

ProgramCompanyFurthest phaseStudies
teprotumumabruleAmgenphase 418
veligrotugruleviridian-therapeutics-incphase 47
linsitinibruleAstellas Pharmaphase 313
MHB018AruleMinghui Pharmaceuticalphase 36
IBI3031ruleInnovent Biologicsphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07113262Graves Ophthalmopathy · China3RecruitingDec 31, 2026111
NCT06525506Graves Ophthalmopathy · China2CompletedJan 9, 202538
NCT06126783Graves Ophthalmopathy · China3CompletedSep 23, 202591
NCT05795621Graves Ophthalmopathy · China3CompletedDec 20, 2023115
NCT05480579Healthy · China1CompletedNov 23, 202228

How it is read

Names in the registry

  • “IBI311”, 7 entries
  • “IBI311 (20 mg)”, 1 entry
  • “IBI311 (3-20 mg)”, 1 entry
  • “IBI311 (10 mg)”, 1 entry
  • “IBI311 (3-10mg/kg)”, 1 entry

Codes read as this program: IBI311.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.